Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

BACKGROUND: Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these patients will develop distant metastases (DM) within...

Descripción completa

Detalles Bibliográficos
Autores principales: Haist, Maximilian, Stege, Henner, Rogall, Friederike, Tan, Yuqi, von Wasielewski, Imke, Klespe, Kai Christian, Meier, Friedegund, Mohr, Peter, Kähler, Katharina C, Weichenthal, Michael, Hauschild, Axel, Schadendorf, Dirk, Ugurel, Selma, Lodde, Georg, Zimmer, Lisa, Gutzmer, Ralf, Debus, Dirk, Schilling, Bastian, Kreuter, Alexander, Ulrich, Jens, Meiss, Frank, Herbst, Rudolf, Forschner, Andrea, Leiter, Ulrike, Pfoehler, Claudia, Kaatz, Martin, Ziller, Fabian, Hassel, Jessica C, Tronnier, Michael, Sachse, Michael, Dippel, Edgar, Terheyden, Patrick, Berking, Carola, Heppt, Markus V, Kiecker, Felix, Haferkamp, Sebastian, Gebhardt, Christoffer, Simon, Jan Christoph, Grabbe, Stephan, Loquai, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510881/
https://www.ncbi.nlm.nih.gov/pubmed/37730278
http://dx.doi.org/10.1136/jitc-2023-007630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510881/
https://www.ncbi.nlm.nih.gov/pubmed/37730278
http://dx.doi.org/10.1136/jitc-2023-007630

Ejemplares similares